Q-omics provides the consensus-scored CICP9 profile across patient tissues and cancer cell-line models. CICP9 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CICP9 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, CICP9 RNA expression shows 15,883 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, THCA, and THYM as cancer lineages where CICP9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CICP9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CICP9 survival associations across molecular data types. CICP9 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CICP9 RNA expression–survival associations across cancer types. High CICP9 expression shows unfavorable associations in ACC, UCEC, LIHC, BRCA and PCPG, but favorable associations in SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for CICP9 RNA expression.
This table summarizes CICP9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CICP9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CICP9 shows lower tumor expression in THCA, UCEC and BLCA and higher tumor expression in LIHC, CHOL and STAD. The THCA box plot shows higher CICP9 RNA expression in normal versus tumor tissue (log2 FC = −0.055, t-test p < 0.001).
This table shows molecular features associated with CICP9 in patient tissues and cancer cell lines. In patient samples, CICP9 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
